Every AGA compound in clinical development. No blogspam, just data.
| Compound | Phase | Type | ||||
|---|---|---|---|---|---|---|
| Ritlecitinib Litfulo | Approved | Oral | ||||
CompanyPfizer Statusapproved Est. ReleaseAvailable (AA only) MechanismJAK3/TEC Inhibitor SummaryJAK inhibitor approved for alopecia areata (autoimmune). Does NOT work for male/female pattern baldness (AGA). Often confused but different conditions entirely. LatestFDA approved for alopecia areata (autoimmune hair loss). NOT for androgenetic alopecia. No curated threads. Search Reddit | ||||||
| Baricitinib Olumiant | Approved | Oral | ||||
CompanyEli Lilly Statusapproved Est. ReleaseAvailable (AA only) MechanismJAK1/JAK2 Inhibitor SummaryAnother JAK inhibitor for alopecia areata. Like ritlecitinib, does NOT treat androgenetic alopecia. Systemic drug with immune effects. LatestFDA approved for alopecia areata. Also approved for rheumatoid arthritis. No curated threads. Search Reddit | ||||||
| Clascoterone Breezula / CB-03-01 / Winlevi | Phase 3 | Topical | ||||
CompanyCassiopea Statusactive Est. Release2027 MechanismAndrogen Receptor Antagonist SummaryTopical anti-androgen that blocks DHT at the scalp without systemic effects. 1% already FDA approved for acne (Winlevi). Higher concentrations (2.5-7.5%) being tested for hair loss. Phase 3 results show statistically significant hair count increases vs placebo. LatestPhase 3 topline results released Dec 2025. Testing 2.5-7.5% concentrations for AGA. Market release estimated 2027 if approved. | ||||||
| Pyrilutamide KX-826 / Koshine | Phase 3 | Topical | ||||
CompanyKintor Pharmaceutical Statusactive Est. Release2027 (China) MechanismAndrogen Receptor Antagonist SummaryTopical anti-androgen that failed to show statistical significance vs placebo in Phase 3. Now being sold as cosmetic to bypass approval. Long-term safety data showed modest results (46% got ≥10 hairs/cm² over 52 weeks). Kintor's GT20029 is now seen as more promising. LatestPhase 3 (0.5%) failed primary endpoint Nov 2023 - no statistical significance vs placebo. New 1% trial ongoing but Phase 2 showed minimal improvement over 0.5%. Already sold as cosmetic (Koshine) on Amazon. NDA submission to China expected 2026. | ||||||
| GT20029 AR-PROTAC | Phase 3 | Topical | ||||
CompanyKintor Pharmaceutical Statusactive Est. Release2027-2028 MechanismPROTAC Androgen Receptor Degrader SummaryFirst-in-class PROTAC technology that degrades androgen receptors rather than just blocking them. Novel mechanism could be more effective than traditional anti-androgens. Phase 2 showed all treatment groups had hair count increases vs placebo. LatestPhase 2 complete. Phase 3 started 2025, expected to finish ~2026. Market release 2027-2028 if successful. | ||||||
| PP405 | Phase 2 | Topical | ||||
CompanyPelage Pharmaceuticals Statusactive Est. Release2028-2029 MechanismMitochondrial Pyruvate Carrier (MPC) Inhibitor SummaryNovel MPC inhibitor that reprograms hair follicle metabolism, pushing stem cells from oxidative phosphorylation into a glycolytic state (mimicking active growth phase). NOT an androgen blocker - works on men and women. Backed by ARCH Ventures and Google Ventures. Fast response in trials (8 weeks vs typical 6-12 months). LatestPhase 2a complete - 31% of men showed >20% hair density increase at 8 weeks (vs 0% placebo). No systemic absorption detected. Phase 2b expected to finish end of 2025, Phase 3 by 2027. $120M Series B funding secured. Reddit (4)Pelage Pharmaceuticals has secured $120 million in funding 2025-10-15 · 400 pts ·
r/tressless
Don't Get Too Hyped About PP405. We've Seen This Movie Before. 2025-06-18 · 219 pts ·
r/tressless
PP405 Phase 2a press release with early results 2025-06-17 · 694 pts ·
r/tressless
UCLA scientists found a molecule — PP405 — that wakes up sleeping hair follicles 2025-05-12 · 1353 pts ·
r/tressless
| ||||||
| Verteporfin Visudyne | Phase 2 | Injectable | ||||
CompanyVarious (Off-label) Statusactive Est. ReleaseTBD MechanismYAP/TAZ Inhibitor (Scarless Healing) SummaryOriginally for eye disease, now being tested for scarless healing in hair transplants. Could enable unlimited donor harvesting by preventing scar formation. Potentially game-changing for transplant patients. LatestMulti-center trial recruitment ongoing. FDA approved for macular degeneration, being explored for scarless wound healing in transplants. | ||||||
| VDPHL01 Veradermics | Phase 2 | Oral | ||||
CompanyVeradermics Statusactive Est. Release2027-2028 MechanismExtended-Release Minoxidil SummaryExtended-release oral minoxidil designed to minimize cardiovascular side effects seen with regular oral min. Non-hormonal approach (doesn't touch DHT). Phase 2/3 showing impressive early results. Major funding and fast-tracking suggest serious commercial intent. LatestPhase 2/3 enrollment completed Dec 2025. +47.3 hairs/cm² at 4 months with 95% satisfaction rate. $150M Series C secured Oct 2025. FDA approval expected late 2027 - mid 2028. | ||||||
| HMI-115 | Phase 2 | Injectable | ||||
CompanyHope Medicine Statusactive Est. Release2027 MechanismProlactin Receptor Antibody SummaryMonoclonal antibody blocking prolactin receptors in hair follicles. Phase 1b showed +14 hairs/cm² over 24 weeks. Completely different mechanism from anti-androgens - targets PRLR pathway. Licensed from Bayer. Macaque monkey studies showed dramatic regrowth. LatestPhase 2 completed Nov 2024, results pending. Phase 1b showed +14 hairs/cm² in males. Company targeting 2027 release. Reddit (4)Hope Medicine's HMI-115 could be out in 2027 per Company Founder 2025-05-25 · 35 pts ·
r/tressless
2-month HMI-115 results from the Chinese trial 2024-05-16 · 67 pts ·
r/tressless
HMI 115 Phase 2 - Leaked pics from Discord 2024-05-03 · 362 pts ·
r/tressless
HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement 2023-10-27 · 109 pts ·
r/tressless
| ||||||
| Follicopeptide FOL-005 / FOL005 | Phase 2 | Topical | ||||
CompanyCoegin Pharma Statusactive Est. Release2025-2026 MechanismOsteopontin Peptide (Stem Cell & Angiogenesis) SummaryModified osteopontin peptide that activates stem cells, promotes blood vessel growth around follicles. Launching as cosmetic (not drug) for faster market access. Trial results showed ~12 hairs/cm² increase after 4 months - comparable to finasteride. Originally developed by Follicum, acquired by Coegin Pharma. LatestLaunching as cosmetic late 2025/early 2026 via Scandinavian Biolabs and Hårklinikken partnerships. ~12 hairs/cm² increase in trials - similar to finasteride. | ||||||
| AMP-303 SCUBE3 | Phase 1 | Injectable | ||||
CompanyAmplifica Statusactive Est. Release2028+ MechanismSignaling Molecule (Hair Follicle Activation) SummaryNovel polysaccharide intradermal injectable that activates dormant hair follicles using unique signaling molecules. Nature-inspired approach from UCI research. Phase 1 showed 15% hair increase in 60 days. Co-founded by hair transplant surgeon Dr. William Rassman. LatestPhase 1 completed Jan 2025. 15% increase in non-vellus hair at 60 days. Results presented at 2025 SID meeting. Co-founded by Dr. William Rassman (active on r/tressless). Reddit (3)Amplifica is working on 3 Programs: AMP-303 / AMP-203 & AMP-506 / AMP-601 2025-03-11 · 27 pts ·
r/tressless
Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days! 2025-01-15 · 102 pts ·
r/tressless
New drug for hair loss announced by Amplifica 2023-01-26 · 166 pts ·
r/tressless
| ||||||
| ET-02 | Phase 1 | Topical | ||||
CompanyEirion Therapeutics Statusactive Est. Release2028+ MechanismPAI-1 Inhibitor (Stem Cell Activation) SummaryPAI-1 inhibitor that targets stem cell biology to restore normal hair follicle function. Phase 1 showed 6-fold increase in non-vellus hair in just 5 weeks - outperformed 4 months of minoxidil. Also may reverse hair graying. Non-hormonal, no sexual side effects expected. Being tested in oral form too. LatestPhase 1 completed Jan 2025 with unprecedented results. 6-fold increase in hair count in 5 weeks. Phase 2 with ~150 participants planned for 2025. Reddit (3)Why does Pelage PP405 receive so much attention, while Eirion ET-02 seems forgotten? 2025-06-24 · 31 pts ·
r/tressless
I hope ET-02 or PP405 will be released in the next 4-5 years 2025-06-10 · 16 pts ·
r/tressless
Et-02 phase one clinic trial results successful! 2025-01-10 · 48 pts ·
r/tressless
| ||||||
| OLX104C OLX72021 | Phase 1 | Injectable | ||||
CompanyOliX Pharmaceuticals Statusactive Est. Release2027+ MechanismRNA Interference (Androgen Receptor silencing) SummaryKorean biotech using asymmetric siRNA (asiRNA) to silence androgen receptor expression in hair follicles. Unlike DHT blockers, targets the receptor itself. Injected locally into scalp, rapidly degrades in blood - potentially avoiding sexual dysfunction and depression. Single dose inhibits AR for 3+ weeks. LatestPhase 1 started June 2023 in Australia. Enrolling 120 men across 10 sites. 30-month trial. Scalp injection that degrades in blood - avoids systemic side effects. | ||||||
| Hair Cloning YCH001 | Preclinical | Cell Therapy | ||||
CompanyYunce Medical Statusresearch Est. Release2027 MechanismiPSC-derived Hair Follicle Regeneration SummaryChinese biotech pursuing iPSC-derived hair follicle regeneration, similar to Stemson's approach. Claims >90% CD200 positive cell differentiation (vs 30% in literature). Based in Chengdu, partnered with West China Hospital. Positioning as Stemson's successor after their shutdown. LatestAnimal trials complete. Human clinical trials planned for 2026. Seeking $2M funding. Partnership with West China Hospital of Sichuan University. | ||||||
| 2-Deoxy-D-Ribose 2dDR / Deoxyribose Sugar | Preclinical | Topical | ||||
CompanyUniversity of Sheffield Statusresearch Est. ReleaseTBD MechanismAngiogenesis (Blood Vessel Formation) SummaryA naturally occurring sugar molecule (part of DNA backbone) that promotes blood vessel formation. Sheffield/COMSATS researchers noticed faster hair growth around healing wounds treated with 2dDR. Mouse study showed similar efficacy to minoxidil. Very early stage - researchers explicitly warned against companies selling it prematurely. LatestPublished June 2024 in Frontiers in Pharmacology. Mouse study showed 2dDR gel 80-90% as effective as minoxidil. Researchers cautioned against premature use - no human safety/efficacy data yet. Reddit (5)Novel Formulation To Put An End To Hair Loss Once And For All 2025-11-06 · 120 pts ·
r/tressless
7 months 2DDR treatment, photos 2025-10-01 · 7 pts ·
r/tressless
two months on 2-deoxy-d-ribose (2ddr) 2025-06-28 · 10 pts ·
r/tressless
2ddr thread, I'll try to add to it monthly 2025-04-05 · 18 pts ·
r/tressless
Thoughts on this 2-deoxy-D-ribose Topical? 2024-07-28 · 26 pts ·
r/tressless
| ||||||
| MicroRNA Therapy miR-218-5p | Preclinical | Topical | ||||
CompanyVarious (Research) Statusresearch Est. Release2029+ MechanismGene Expression Modulation SummaryResearch showing specific microRNAs can trigger significant hair regrowth in mice by softening stiffened stem cells. Northwestern's June 2023 study is the most recent. Promising but very early - years from human trials. LatestNorthwestern study (June 2023) showed softening stem cells via miR-205 restored hair growth in aged mice. Still preclinical, no human trials announced. | ||||||
| Exosomes | Preclinical | Injectable | ||||
CompanyVarious Statusresearch Est. Release2029+ MechanismExtracellular Vesicle Signaling SummaryExtracellular vesicles that carry growth factors and signaling molecules. Early studies show potential for stimulating hair growth. Still very experimental with no standardized protocols or advanced trials. LatestStill in pilot and preclinical studies. No advanced clinical phase expected before 2026. | ||||||
| Oleic Acid Serum | Preclinical | Topical | ||||
CompanyNational Taiwan University Statusresearch Est. ReleaseTBD MechanismHair Follicle Stem Cell Activation via Fatty Acid Metabolism SummarySerum using monounsaturated fatty acids (oleic acid, palmitoleic acid) dissolved in alcohol. Developed by Prof. Sung-Jan Lin at NTU. Activates hair follicle stem cells by mimicking the fat breakdown that occurs during skin healing. No DHT involvement - completely different pathway. Promising mouse data but years from human validation. LatestPublished in Cell Metabolism Oct 2025. Mouse studies showed hair regrowth in 20 days. Professor Lin self-tested on leg with results in 3 weeks. Human scalp trials planned, no timeline. Reddit (3)Where to buy Oleic acid, Palmitoleic acid and anhydrous ethanol? 2025-11-09 · 4 pts ·
r/tressless
Uh oh! 20 days?! Could it be so LOL 2025-10-28 · 784 pts ·
r/tressless
Taiwan scientists used naturally derived fatty acids serum to regrow hairs (in mice) 2025-10-27 · 94 pts ·
r/tressless
| ||||||
| Bee Venom (Melittin) Apitoxin | Preclinical | Topical | ||||
CompanyVarious (Research) Statusresearch Est. ReleaseTBD MechanismIGF-1/VEGF Upregulation + Controlled Irritation SummaryMouse studies comparing 0.001% bee venom to 2% minoxidil showed bee venom outperformed in regrowth speed. Proposed mechanism: melittin increases IGF-1 and VEGF around follicles, reduces inflammation, creates controlled irritation similar to microneedling. Major caveat: severe allergic reactions possible. No human trials, purely animal data. LatestMouse studies showed 0.001% bee venom outperformed 2% minoxidil in regrowth speed. No human trials. Allergy risk is major concern. | ||||||
| Hair Cloning | Preclinical | Cell Therapy | ||||
CompanyStemson Therapeutics Statusdiscontinued MechanismiPSC-derived Hair Follicle Cells SummaryWas the leading company pursuing iPSC-derived hair follicle regeneration - the 'holy grail' of unlimited donor hair. Shut down in Dec 2024 before reaching human trials. Yunce Medical (China) is now pursuing similar technology. LatestCompany shut down Dec 2024. Was the leading hair cloning research company in the US. | ||||||
FDA-approved or widely used for androgenetic alopecia.
5-alpha Reductase Inhibitor (Type II)
Gold standard DHT blocker. Blocks ~70% of DHT. FDA approved for AGA. Well-studied, effective for most. Some report sexual side effects (1-2%).
5-alpha Reductase Inhibitor (Type I & II)
Stronger than finasteride - blocks ~90% of DHT. FDA approved for BPH, used off-label for AGA. Often used when fin alone isn't enough.
Potassium Channel Opener (Vasodilator)
Stimulates hair growth via increased blood flow. Works independently of DHT. Topical OTC or oral (off-label, more effective). Warning: toxic to cats.
Wound Healing / Wnt Pathway Activation
Creates micro-wounds that stimulate healing response and Wnt signaling. Often used with minoxidil to enhance absorption. Weekly at 1.5mm depth.